Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
40.00
-0.85 (-2.08%)
At close: Jan 17, 2025, 4:00 PM
40.02
+0.02 (0.05%)
After-hours: Jan 17, 2025, 6:29 PM EST
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for RARE stock have an average target of 92, with a low estimate of 48 and a high estimate of 140. The average target predicts an increase of 130.00% from the current stock price of 40.00.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RARE stock from 15 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 6 | 6 | 6 |
| Buy | 9 | 9 | 9 | 7 | 7 | 8 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 14 | 14 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $135 → $140 | Buy | Maintains | $135 → $140 | +250.00% | Jan 13, 2025 |
| Wedbush | Wedbush | Hold Reiterates $46 → $48 | Hold | Reiterates | $46 → $48 | +20.00% | Jan 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $95 | Strong Buy | Reiterates | $95 | +137.50% | Dec 24, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $75 → $88 | Buy | Maintains | $75 → $88 | +120.00% | Dec 20, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $105 → $102 | Buy | Maintains | $105 → $102 | +155.00% | Nov 21, 2024 |
Financial Forecast
Revenue This Year
550.19M
from 434.25M
Increased by 26.70%
Revenue Next Year
654.85M
from 550.19M
Increased by 19.02%
EPS This Year
-6.36
from -8.25
EPS Next Year
-5.21
from -6.36
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 581.4M | 826.4M | 1.2B | |||
| Avg | 550.2M | 654.9M | 885.2M | |||
| Low | 472.6M | 575.3M | 682.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 33.9% | 50.2% | 78.8% | |||
| Avg | 26.7% | 19.0% | 35.2% | |||
| Low | 8.8% | 4.6% | 4.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -6.26 | -3.83 | -0.66 | |||
| Avg | -6.36 | -5.21 | -3.16 | |||
| Low | -6.56 | -6.03 | -4.87 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.